Diagnosis of H. pylori With Endofaster

Gastric juice analysis in clinical practice: why, how, and when. The experience with EndoFaster

“…In detail, the NPV was >95% in all, but one study. However, in the latter study, histological presence of H. pylori was probably overestimated [37].…”

“…By taking into account all the available data, it emerges that standard biopsy sampling in the stomach could be eventually avoided in several patients with normal-appearing gastric mucosa and without H. pylori infection and atrophy at EndoFaster real-time analysis, with an acceptable risk of false negative cases as low as 3–4 patients every 100 negative tests, or even lower when considering that some false negative results for one finding could be recovered by positive result at the other finding. In detail, a multicentre study found that biopsy sampling could have been eventually avoided in as many as 42% of consecutive patients who underwent upper endoscopy with negative results of the test and without macroscopic lesions at endoscopy [26], and a 71.5% reduction was even observed in another study [37]. On the other hand, beyond reducing useless biopsies, the test would alert the endoscopist to take the standard antral and gastric body mucosa specimens in those patients with positivity for at least one finding, increasing the overall diagnostic yield of successive histology.…”